secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001837607-24-000062
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma Phase 2 chronic migraine study misses primary and secondary endpoints
--------------------------------------------------------------------------------

- Phase 2 chronic migraine interim analysis did not achieve primary or secondary endpoints.
- End-of-Phase 2 meeting with FDA for episodic migraine resulted in preliminary alignment on Phase 3 design.
- Completed $15M private placement with Daewoong; second installment received April 2024.
- Seongsoo (Shawn) Park appointed to Board of Directors as Daewoong's representative.
- Company evaluating next-steps across late-stage clinical pipeline for ABP-450.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000062/0001837607-24-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000062/aeon-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer